Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
Celadon Pharma surges 171% after securing a pivotal supply agreement with its Danish partner.
Celadon Pharmaceuticals PLC (AIM: CEL) saw its value more than double following a supply agreement that will help it fulfil a German medical cannabis contract signed over a year ago.
Celadon Pharmaceuticals (AIM:CEL) shares drop 50% due to funding delays
Shares in Celadon Pharmaceuticals PLC (AIM: CEL) plummeted 50% in early trading due to delays in accessing £1.3 million of funding.